RNA aptamers generated against oligomeric Aβ40 recognize common amyloid aptatopes with low specificity but high sensitivity

PLoS ONE

Volumn 4, Issue 11, 2009, Pages

  Rahimi, Farid ^a   Murakami, Kazuma ^a,c   Summers, Jamie L ^a   Chen, Chi Hong B ^a,b   Bitan, Gal ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APTAMER; THIOFLAVINE; AMYLOID; AMYLOID BETA PROTEIN; LIGAND; PEPTIDE FRAGMENT; SINGLE STRANDED DNA; THIAZOLE DERIVATIVE;

AMINO ACID SEQUENCE; ARTICLE; BETA SHEET; BINDING AFFINITY; CONTROLLED STUDY; MOLECULAR RECOGNITION; RNA SEQUENCE; SENSITIVITY AND SPECIFICITY; ALZHEIMER DISEASE; CHEMISTRY; DENSITOMETRY; DIMERIZATION; HUMAN; METABOLISM; METHODOLOGY; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN SECONDARY STRUCTURE;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN; APTAMERS, NUCLEOTIDE; DENSITOMETRY; DIMERIZATION; DNA, SINGLE-STRANDED; HUMANS; LIGANDS; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN STRUCTURE, SECONDARY; THIAZOLES;

EID: 70450159254     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007694     Document Type: Article

References (64)

1. Alzheimer's Association (2009) Alzheimer's disease facts and figures. Alzheimers Dement 5: 234-270.
2. Monien BH, Apostolova LG, Bitan G (2006) Early diagnostics and therapeutics for Alzheimer's disease-how early can we get there? Expert Rev Neurother 6: 1293-1306.
3. Kawas CH, Corrada MM, Brookmeyer R, Morrison A, Resnick SM, et al. (2003) Visual memory predicts Alzheimer's disease more than a decade before diagnosis. Neurology 60: 1089-1093.
4. Nestor PJ, Scheltens P, Hodges JR (2004) Advances in the early detection of Alzheimer's disease. Nat Med 10 Suppl: S34-41.
5. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat Rev Mol Cell Biol 8: 101-112.
6. Kirkitadze MD, Bitan G, Teplow DB (2002) Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: The emerging role of oligomeric assemblies. J Neurosci Res 69: 567-577.
7. Rahimi F, Shanmugam A, Bitan G (2008) Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disorders. Curr Alzheimer Res 5: 319-341.
8. Kayed R, Glabe CG (2006) Conformation-dependent anti-amyloid oligomer antibodies. Methods Enzymol 413: 326-344.
9. Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, et al. (2005) Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci USA 102: 2273-2276.
10. Pirttilä T, Kim KS, Mehta PD, Frey H, Wisniewski HM (1994) Soluble amyloid β-protein in the cerebrospinal fluid from patients with Alzheimer's disease, vascular dementia and controls. J Neurol Sci 127: 90-95.
11. Lafaye P, Achour I, England P, Duyckaerts C, Rougeon F (2009) Single-domain antibodies recognize selectively small oligomeric forms of amyloid β, prevent Aβ-induced neurotoxicity and inhibit fibril formation. Mol Immunol 46: 695-704.
12. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, et al. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300: 486-489.
13. O'Nuallain B, Wetzel R (2002) Conformational Abs recognizing a generic amyloid fibril epitope. Proc Natl Acad Sci USA 99: 1485-1490.
14. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, et al. (2007) Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2: 18.
15. Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, et al. (2007) Monoclonal antibodies that target pathological assemblies of Aβ. J Neurochem 100: 23-35.
16. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, et al. (2004) Synaptic targeting by Alzheimer's-related amyloid β oligomers. J Neurosci 24: 10191-10200.
17. Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, et al. (2006) Targeting amyloid-β peptide (Aβ) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Aβ precursor protein (APP) transgenic mice. J Biol Chem 281: 4292-4299.
18. Jayasena SD (1999) Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem 45: 1628-1650.
19. Bunka DH, Stockley PG (2006) Aptamers come of age - at last. Nat Rev Microbiol 4: 588-596.
20. Lee JF, Stovall GM, Ellington AD (2006) Aptamer therapeutics advance. Curr Opin Chem Biol 10: 282-289.
21. Weiss S, Proske D, Neumann M, Groschup MH, Kretzschmar HA, et al. (1997) RNA aptamers specifically interact with the prion protein PrP. J Virol 71: 8790-8797.
22. Bibby DF, Gill AC, Kirby L, Farquhar CF, Bruce ME, et al. (2008) Application of a novel in vitro selection technique to isolate and characterise high affinity DNA aptamers binding mammalian prion proteins. J Virol Methods 151: 107-115.
23. Rhie A, Kirby L, Sayer N, Wellesley R, Disterer P, et al. (2003) Characterization of 2′-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion. J Biol Chem 278: 39697-39705.
24. King DJ, Safar JG, Legname G, Prusiner SB (2007) Thioaptamer interactions with prion proteins: sequence-specific and non-specific binding sites. J Mol Biol 369: 1001-1014.
25. Proske D, Gilch S, Wopfner F, Schatzl HM, Winnacker EL, et al. (2002) Prion-protein-specific aptamer reduces PrPSc formation. Chembiochem 3: 717-725.
26. Bunka DH, Mantle BJ, Morten IJ, Tennent GA, Radford SE, et al. (2007) Production and characterization of RNA aptamers specific for amyloid fibril epitopes. J Biol Chem 282: 34500-34509.
27. Ylera F, Lurz R, Erdmann VA, Furste JP (2002) Selection of RNA aptamers to the Alzheimer's disease amyloid peptide. Biochem Biophys Res Commun 290: 1583-1588.
28. Bitan G, Lomakin A, Teplow DB (2001) Amyloid β-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J Biol Chem 276: 35176-35184.
29. Bitan G (2006) Structural study of metastable amyloidogenic protein oligomers by photo-induced cross-linking of unmodified proteins. Methods Enzymol 413: 217-236.
30. Bitan G, Teplow DB (2005) Preparation of aggregate-free, low molecular weight amyloid-β for assembly and toxicity assays. Methods Mol Biol 299: 3-9.
31. Gosal WS, Morten IJ, Hewitt EW, Smith DA, Thomson NH, et al. (2005) Competing pathways determine fibril morphology in the self-assembly of β2-microglobulin into amyloid. J Mol Biol 351: 850-864.
32. Myers SL, Jones S, Jahn TR, Morten IJ, Tennent GA, et al. (2006) A systematic study of the effect of physiological factors on β2-microglobulin amyloid formation at neutral pH. Biochemistry 45: 2311-2321.
33. Sipe JD, Cohen AS (2000) Review: history of the amyloid fibril. J Struct Biol 130: 88-98.
34. Stine WB Jr, Dahlgren KN, Krafft GA, LaDu MJ (2003) In vitro characterization of conditions for amyloid-β peptide oligomerization and fibrillogenesis. J Biol Chem 278: 11612-11622.
35. Bitan G, Fradinger EA, Spring SM, Teplow DB (2005) Neurotoxic protein oligomers - what you see is not always what you get. Amyloid 12: 88-95.
36. LeVine H 3rd (1999) Quantification of β-sheet amyloid fibril structures with thioflavin T. Methods Enzymol 309: 274-284.
37. Khurana R, Coleman C, Ionescu-Zanetti C, Carter SA, Krishna V, et al. (2005) Mechanism of thioflavin T binding to amyloid fibrils. J Struct Biol 151: 229-238.
38. Siddiqui MA, Keating GM (2005) Pegaptanib: in exudative age-related macular degeneration. Drugs 65: 1571-1577; discussion 1578-1579.
39. Takemura K, Wang P, Vorberg I, Surewicz W, Priola SA, et al. (2006) DNA aptamers that bind to PrP(C) and not PrP(Sc) show sequence and structure specificity. Exp Biol Med (Maywood) 231: 204-214.
40. Kouassi GK, Wang P, Sreevatan S, Irudayaraj J (2007) Aptamer-mediated magnetic and gold-coated magnetic nanoparticles as detection assay for prion protein assessment. Biotechnol Prog 23: 1239-1244.
41. Murakami K, Nishikawa F, Noda K, Yokoyama T, Nishikawa S (2008) Antibovine prion protein RNA aptamer containing tandem GGA repeat interacts both with recombinant bovine prion protein and its β isoform with high affinity. Prion 2: 73-80.
42. Lührs T, Zahn R, Wüthrich K (2006) Amyloid formation by recombinant full-length prion proteins in phospholipid bicelle solutions. J Mol Biol 357: 833-841.
43. Fezoui Y, Teplow DB (2002) Kinetic studies of amyloid β-protein fibril assembly. Differential effects of α-helix stabilization. J Biol Chem 277: 36948-36954.
44. Ginsberg SD, Crino PB, Hemby SE, Weingarten JA, Lee VMY, et al. (1999) Predominance of neuronal mRNAs in individual Alzheimer's disease senile plaques. Ann Neurol 45: 174-181.
45. Ginsberg SD, Galvin JE, Chiu TS, Lee VM, Masliah E, et al. (1998) RNA sequestration to pathological lesions of neurodegenerative diseases. Acta Neuropathol 96: 487-494.
46. Marcinkiewicz M (2002) β APP and furin mRNA concentrates in immature senile plaques in the brain of Alzheimer patients. J Neuropathol Exp Neurol 61: 815-829.
47. Calamai M, Taddei N, Stefani M, Ramponi G, Chiti F (2003) Relative influence of hydrophobicity and net charge in the aggregation of two homologous proteins. Biochemistry 42: 15078-15083.
48. Maury CP (2009) Self-propagating β-sheet polypeptide structures as prebiotic informational molecular entities: the amyloid world. Orig Life Evol Biosph 39: 141-150.
49. Haller AA, Sarnow P (1997) In vitro selection of a 7-methyl-guanosine binding RNA that inhibits translation of capped mRNA molecules. Proc Natl Acad Sci USA 94: 8521-8526.
50. Mannironi C, Di Nardo A, Fruscoloni P, Tocchini-Valentini GP (1997) In vitro selection of dopamine RNA ligands. Biochemistry 36: 9726-9734.
51. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, et al. (2003) Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways. Proc Natl Acad Sci USA 100: 330-335.
52. Rahimi F, Maiti P, Bitan G (2009) Photo-induced cross-linking of unmodified proteins (PICUP) applied to amyloidogenic peptides. J Vis Exp 23: http://www.jove.com/pubmedgen/default.aspx?PDF=&ID=1071.
53. Gopinath SC (2007) Methods developed for SELEX. Anal Bioanal Chem 387: 171-182.
54. Ulrich H (2006) RNA aptamers: from basic science towards therapy. Handb Exp Pharmacol. 305-326.
55. Chen CH, Chernis GA, Hoang VQ, Landgraf R (2003) Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. Proc Natl Acad Sci USA 100: 9226-9231.
56. Bailey TL, Elkan C (1994) Fitting a mixture model by expectation maximization to discover motifs in biopolymers. Proc Int Conf Intell Syst Mol Biol 2: 28-36.
57. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, et al. (2007) Clustal W and Clustal X version 2.0. Bioinformatics 23: 2947-2948.
58. Zuker M (2003) Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31: 3406-3415.
59. Arvinte T, Cudd A, Drake AF (1993) The structure and mechanism of formation of human calcitonin fibrils. J Biol Chem 268: 6415-6422.
60. Porat Y, Mazor Y, Efrat S, Gazit E (2004) Inhibition of islet amyloid polypeptide fibril formation: a potential role for heteroaromatic interactions. Biochemistry 43: 14454-14462.
61. Podesta A, Tiana G, Milani P, Manno M (2006) Early events in insulin fibrillization studied by time-lapse atomic force microscopy. Biophys J 90: 589-597.
62. Morozova-Roche LA, Zurdo J, Spencer A, Noppe W, Receveur V, et al. (2000) Amyloid fibril formation and seeding by wild-type human lysozyme and its disease-related mutational variants. J Struct Biol 130: 339-351.
63. Tagliavini F, Prelli F, Verga L, Giaccone G, Sarma R, et al. (1993) Synthetic peptides homologous to prion protein residues 106-147 form amyloid-like fibrils in vitro. Proc Natl Acad Sci USA 90: 9678-9682.
64. Abramoff MD, Magelhaes PJ, Ram SJ (2004) Image Processing with ImageJ. Biophotonics Intl 11: 36-42.